News - Amorchem

May 21, 2024 AmorChem’s RNA Zipcode delivery technology investment exits via New York-based Kodikaz Therapeutic Solutions, Inc. Read article

August 10, 2023 Novo Nordisk to acquire Inversago Pharma to develop new therapies for people living with obesity, diabetes and other serious metabolic diseases Read article

August 1, 2023 Sygnature Discovery Accelerates Global Growth with Major North American Acquisition Read article

February 15, 2023 AmorChem Promotes Dr. Kevin McBride to General Partner Read article

March 15, 2022 Inversago Pharma Announces Dosing of First Participant with Metabolic Syndrome in Phase 1B Clinical Trial Read article

January 12, 2022 CQDM partners with Neurasic Therapeutics, HBHL and the Louise and Alan Edwards Foundation to fund a non-opioid pain treatment discovery Read article

May 19, 2021 Giiant Pharma Inc. announced the closing of US$11M in Seed financing to develop its Precision Delivery technology platform in gastroenterology. Read article

June 4, 2020 AmorChem invests in a potential treatment for cerebral amyloid angiopathy and Alzheimer’s disease Read article

June 3, 2020 AmorChem invests in the work of Sidong Huang at McGill University Read article